Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > April 24, 2020
Daily News
April 24, 2020
- Japan Moving to Thwart Foreign Takeover of Drug, Medical Devices Makers
April 24, 2020
- Chugai’s Q1 Earnings Brisk on Hemlibra, Oncology Franchise
April 24, 2020
- Life Science Institute’s Muse Cell Product Shows Safety, Tolerability in 2 Trials
April 24, 2020
- Biogen Delays US Aducanumab Filing to Q3, but Keeps Japan’s 2020 Plan Intact
April 24, 2020
- CMIC Group to Support Clinical Trial, Manufacturing of Avigan for COVID-19 Treatment
April 24, 2020
- Kyorin’s Coronavirus Detection Reagent Now Available
April 24, 2020
- Relugolix Combo Improves Endometriosis, Non-Menstrual Pelvic Pain in PIII: Myovant
April 24, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…